Proteomics profiling of end-stage COVID-19 diseased human lungs

Lung biopsies were collected from recently deceased patients, who tested positive and were treated for SARS-CoV-2 infections, or from patients that succumbed to a non-inflammatory unrelated disease, serving as control. Two samples were taken from each patient either from macroscopically affected lung tissue, for SARS-CoV-2 patients, or healthy homogeneous lung parenchyma of the control patients. All samples were then subjected to shotgun proteomics analysis using data independent acquisition approach.